The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study.

Front Oncol · 2021 · PMC8721033 · PMID 34988019

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In the KEYNOTE-240 study, although OS and PFS did not reach statistical significance, ORR and overall response were better than those of placebo, and some patients benefited from pembrolizumab ( 12 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.